EGFR and non-small cell lung carcinoma: Although no quantitative threshold of EGFR mutation has been established to identify NSCLC patients that might benefit of treatment with EGFR TKIs, previous studies have suggested a correlation between the “amount” of EGFR mutation and the extent of the response to these agents [22, 30, 31].